Overview

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Status:
Unknown status

Trial end date:
2020-10-31

Target enrollment:

Participant gender:

Summary

This is a randomized, multicenter, open, controlled Post-Marketing Study. 272 early stage female breast cancer patients who were histopathology confirmed with adjuvant chemotherapy indications were enrolled in this study .The subjects will be randomly assigned to one of the two treatment groups at a 1: 1 ratio, and stratified by trastuzumab,age,baseline cardiac risk factors.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin
Paclitaxel